Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P695 Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

A. Gutiérrez Casbas1, L. Sempere Robles2, R. Muñoz Pérez2, A. Rodríguez Angulo2, S. Climent3, J.I. Cameo Lorenzo2, M. Díaz3, P. Boada3, P. Más-Serrano3

1Department of Gastroenterology- CIBERehd, Hospital General Universitario Alicante, Alicante, Spain, 2Department of Gastroenterology, Hospital General Universitario Alicante, Alicante, Spain, 3Department of Pharmacy, Hospital General Universitario Alicante, Alicante, Spain

P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1

ECCO'20 Vienna

Year: 2020
Authors:

M. Kubota Kajiwara, K. Uchiyama, Y. Azuma, R. Yasuda, S. Takayama, T. Takagi, Y. Naitoh

Kyoto Prefectural University of Medicine, Gastroenterology and Hepatology, Kyoto, Japan

P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia

ECCO'20 Vienna

Year: 2020
Authors:

P. Kakkadasam Ramaswamy, H. Moattar, E. Sawyer, J. Edwards, D. Shukla

Department of Gastroenterology, Gold Coast University Hospital, Southport, Australia

P698 IBD patients equally tolerate bowel preparation but need higher doses of sedation during colonoscopy in comparison with a population screening programme: Results from a prospective, single-centre study

ECCO'20 Vienna

Year: 2020
Authors:

C. Bezzio1, P. Andreozzi2, M. Schettino1, I. Arena1, C. Della Corte1, M. Devani1, G. Manes1, B. Omazzi1, S. Saibeni1

1Gastroenterology Unit, ASST Rhodense - Ospedale di Rho, Rho, Italy, 2Gastroenterology Unit, Marcianise Hospital, Marcianise, Italy

P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme

ECCO'20 Vienna

Year: 2020
Authors:

M.C. Dubinsky1, A.G. Bushmakin2, J.C. Cappelleri2, J. Woolcott3, P. Sharma4, E. Maller3, L. Salese3, A. Armuzzi5

1Icahn School of Medicine at Mount Sinai, New York, New York, USA, 2Pfizer Inc., Groton, Connecticut, USA, 3Pfizer Inc., Collegeville, Pennsylvania, USA, 4Pfizer Inc., New York, New York, USA, 5IBD Unit- Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

P700 Effect of vitamin D in disease activity score and clinical relapse in patients with inflammatory bowel disease: A systematic review and meta-analysis

ECCO'20 Vienna

Year: 2020
Authors:

Y. Guzman1, O. Samson1, J.P. Segal2, J.K. Limdi3, B. Hayee4

1NA, na, Bournemouth, UK, 2London North West University Healthcare, NHS Trust, London, UK, 3Pennine Acute Hospitals, NHS Trust, Oldham, UK, 4King’s College Hospital, NHS Foundation Trust, London, UK

P701 New onset spondyloarthropathy in vedolizumab treated IBD patients

ECCO'20 Vienna

Year: 2020
Authors:

A.M. Tetley1, T. Lobaton2, M. Truyens2, K.H. Katsanos3, K.H.N. de Boer4, A. Pattinson5, T. Molnar6, R. Filip7, G. Michalopoulos8, S. Sebastian5

1Gastroenterology, Hull York Medical School, Hull, UK, 2Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium, 3University of Ioannina School of Health Sciences, Division of Gastroenterology, Ioannina, Greece, 4Department of Gastroenterology and Hepatology, Amsterdam UMC- VU University Medical Center, Amsterdam, Netherlands Antilles, 5IBD Unit- Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK, 6First Department of Medicine, University of Szeged, Szeged, Hungary, 7Department of Gastroenterology, Clinical Hospital 2- University of Rzeszow, Rzeszow, Poland, 8Gastroenterology Department, Tzaneion General Hospital of Piraeus, 8, Piraeus, Greece

P702 Treatment decisions in older inflammatory bowel disease patients: Applying gut feeling in an evidence-based era? A qualitative study

ECCO'20 Vienna

Year: 2020
Authors:

S. Waars1, V. Asscher1, A. Pieterse2, A. van der Meulen-de Jong1, S. Mooijaart3,4, J. Maljaars1

1Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands, 2Medical Decision Making- Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands, 3Department of Geriatrics and Gerontology, Leiden University Medical Centre, Leiden, The Netherlands, 4Institute for Evidence-Based Medicine in Old Age IEMO, Institute for Evidence-Based Medicine in Old Age IEMO, Leiden, The Netherlands

P703 Addition of azathioprine to switch of anti-TNF in patients with IBD in clinical relapse with pharacokinetic failure: A post hoc analysis of a prospective randomised trial using drug-tolerant assay

ECCO'20 Vienna

Year: 2020
Authors:

S. Paul1, N. Williet2, S. Nancey3, P. Veyrard2, G. Boschetti3, A.E. Berger1, B. Flourie3, L. Peyrin Biroulet4, X. Roblin2

1Immunology, CHU Saint Etienne, Hospital Nord, Saint Priest en Jarez, France, 2Department of Gastroenterology and Hepatology, Inserm CIC1408, CHU Saint Etienne, Hospital Nord, Saint Priest en Jarez, France, 3CHU Lyon, Gastroenterology, Lyon, France, 4CHU Nancy, Gastroenterology, Nancy, France

P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study

ECCO'20 Vienna

Year: 2020
Authors:

C. Liatsos1, A. Papaefthymiou1, N. Kyriakos1, M. Giakoumis1, M. Tzouvala2, M. Doulberis3, C. Mavrogiannis4, J. Kountouras5

1Department of Gastroenterology, 401 General Military Hospital of Athens, Athens- Attica, Greece, 2Department of Gastroenterology, Agios Panteleimon General Hospital, Nikaia- Attica, Greece, 3Department of Gastroenterology and Hepatology, University of Zurich, Zurich, Switzerland, 4Faculty of Nursing- School of Public Health, National and Kapodistrian University of Athens, Athens- Attica, Greece, 5Department of Internal Medicine- Second Medical Clinic, Ippokration Hospital- Aristotle University of Thessaloniki, Thessaloniki- Macedonia, Greece

P705 Dietary practices and beliefs of patients with older-onset inflammatory bowel disease: A prospective UK study

ECCO'20 Vienna

Year: 2020
Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

1Department of Gastroenterology, Northern Care Alliance, Manchester, UK, 2Division of Diabetes- Endocrinology and Gastroenterology, University of Manchester, Manchester, UK

P706 Adalimumab drug levels at secondary loss of response in Crohn’s disease; are we aiming high enough? A retrospective, international multi-centre study

ECCO'20 Vienna

Year: 2020
Authors:

A. Swaine1, R. Reynolds2, X. Roblin3, D. Gibson1, C. Martin4, P. Irving2, M. Sparrow1, M. Ward1

1Gastroenterology, Alfred Hospital, Melbourne, Australia, 2Gastroenterology, Guys and St Thomas’ Trust, London, UK, 3Gastroenterology, CHU de St. Etienne, St. Etienne, France, 4Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia

P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study

ECCO'20 Vienna

Year: 2020
Authors:

R. Filip1,2, S. Jarmakiewicz - Czaja3, D. Piątek4, J. Sztembis5, A. Pękala1, W. Guz6

1Department of Gastroenterology with IBD Unit, Clinical Hospital No.2- Rzeszow, Rzeszow, Poland, 2Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland, 3Institute of Health Sciences, Medical College of Rzeszow University, Rzeszow, Poland, 4Department of Conservative Dentistry with Endodontics, Medical University of Lublin, Lublin, Poland, 5Department of Internal Medicine- Endocrinology- Nephrology, Clinical Hospital No.2 Rzeszow, Rzeszow, Poland, 6Medical College of Rzeszow University

P708 The effect of psychotherapy on quality of life in inflammatory bowel disease patients: A systematic literature review

ECCO'20 Vienna

Year: 2020
Authors:

E. Paulides1,2, I. Boukema2, C.J. van der Woude1, N.K.H. de Boer2

1ErasmusMC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2Amsterdam UMC- location vumc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands

P709 Is azathioprine safe as long-term treatment in paediatric patients with inflammatory bowel disease?

ECCO'20 Vienna

Year: 2020
Authors:

M.A. Martínez Ibeas, I. Bacelo Ruano, S. Rodríguez Manchón, M. Velasco Rodríguez-Belvís, J.F. Viada Bris, G. Domínguez Ortega, R.A. Muñoz Codoceo

Paediatric Gastroenterology and Nutrition Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain

P710 The influence of probiotics to the efficacy of 5-ASA for the patients of ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

R. YASUDA, K. Uchiyama, T. Takagi, M. Kubota, S. Sugino, Y. Azuma, H. Kitae, T. Torii, S. Takayama, K. Inoue, K. Katada, K. Kamada, T. Ishikawa, H. Konishi, Y. Naito, Y. Itoh

Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine- Graduate School of Medical Science, Kyoto, Japan

P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Guardiola Capón1, K. SERRA1, L. Rodríguez-Alonso1, E. Santacana2, A. Padró3, N. Padullés2, A. Ruiz-Cerulla1, C. Arajol1, B. Camps1, G. Surís1, J. Orobitg1, F. Rodríguez-Moranta1

1Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain, 2Hospital Universitari de Bellvitge, Pharmacy, Barcelona, Spain, 3Hospital Universitari de Bellvitge, Clinical Genetics Laboratory, Barcelona, Spain

P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

K. Li1, F. Yang1, C. Marano1, H. Zhang2, W.J. Sandborn3, B.E. Sands4, B.G. Feagan5, D.T. Rubin6, L. Peyrin-Biroulet7, J.R. Friendman1, G. De Hertogh8

1UNIFI Investigators, 1Janssen Research & Development- LLC, Immunology, Spring House, USA, 2Janssen Research & Development- LLC, Clinical Biostats, Spring House, USA, 3University of California San Diego, Gastroenterology, La Jolla, USA, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, USA, 5Robarts Research Institute, Robarts Clinical Trials, London, Canada, 6University of Chicago Medicine, Gastroenterology, Chicago, USA, 7Nancy University Hospital- Université de Lorraine, Gastroneterology, Nancy, France, 8University Hospitals KU Leuven, Pathology, Leuven, Belgium

P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn’s disease in the UK and Ireland: OCTAVO cohort 2

ECCO'20 Vienna

Year: 2020
Authors:

G. Parkes1, A. Akbar2, I. Beales3, M. Buckley4, T. Creed5, S. Din6, A. Fraser5, N. Plevris7, S. Meadowcroft8, G. Owen9, N. Heggs8, OCTAVO

1Department of Gastroenterology, The Royal London Hospital- Barts Health NHS Trust, London, UK, 2Gastroenterology Department, St Mark’s Hospital and Academic Institute-, London, UK, 3Department of Gastroenterology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK, 4Department of Gastroenterology, Mercy University Hospital, Cork, Ireland, 5Gastroenterology Department, Bristol Royal Infirmary- University Hospitals Bristol NHS Foundation Trust, Bristol, UK, 6Department of Gastroenterology, University Hospitals of Derby and Burton NHS Foundation Trust- Royal Derby Hospital, Derby, UK, 7Gastroenterology, The Edinburgh IBD Unit- Western General Hospital, Edinburgh, UK, 8Medical Department, Takeda UK Ltd, London, UK, 9Market Access, Takeda UK Ltd, London, UK

P714 Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study

ECCO'20 Vienna

Year: 2020
Authors:

C. ERIKSSON1, S. Rundquist1, V. Lykiardopoulos2, R. Udumyan3, P. Karlén4, O. Grip5, C. Söderman6, S. Almer7, E. Hertervig8, J. Gunnarsson9, C. Malmgren10, J. Delin11, H. Strid12, M. Sjöberg13, D. Öberg14, D. Bergemalm1, H. Hjortswang2, J. Halfvarson1

1The SWIBREG SVEAH Study Group, 1Department of Gastroenterology, Faculty of Medicine and Health- Örebro University, Örebro, Sweden, 2Department of Gastroenterology, Linköping University, Linköping, Sweden, 3Clinical Epidemiology and Biostatistics, School of Medical Sciences- Örebro University, Örebro, Sweden, 4Department of Internal Medicine, Danderyd Hospital, Stockholm, Sweden, 5Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden, 6Department of Internal Medicine, St Göran Hospital, Stockholm, Sweden, 7IBD-Unit-Gastroenterology, Karolinska University Hospital, Stockholm, Sweden, 8Department of Gastroenterology, Skåne University Hospital, Lund, Sweden, 9Department of Internal Medicine, Kungälv Hospital, Kungälv, Sweden, 10Takeda Pharma AB, Takeda, Stockholm, Sweden, 11Department of Gastroenterology, Ersta Hospital, Stockholm, Sweden, 12Department of Internal Medicine, Södra Älvs.borgs Hospital, Borås, Sweden, 13Department of Internal Medicine, Skaraborgs Hospital, Lidköping, Sweden, 14Department of Internal Medicine, Sunderby Hospital, Sunderbyn, Sweden